why choose us

First received: September 20, 2023

Clinical Trial: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)

Brief Summary: Primary Objective• Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI).Secondary ObjectivesTo assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity.To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations.To determine pharmacodynamic (PD) changes with…

Read more